The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

Comparison of the quality of life of early and advanced stage ovarian cancer survivors.

Print

Sub-category:
Ovarian Cancer

Category:
Gynecologic Cancer

Meeting:
2008 ASCO Annual Meeting

Session Type and Session Title:
Poster Discussion, Gynecologic Cancer

Abstract No:
5528

Citation:
J Clin Oncol 26: 2008 (May 20 suppl; abstr 5528)

Author(s):
K. Mirabeau-Beale, A. B. Kornblith, R. T. Penson, H. Lee, A. Goodman, S. M. Campos, L. R. Duska, L. Pereira, C. D. Gibson, U. A. Matulonis

Abstract:

Background: No direct quality of life (QOL) comparisons have been performed based on ovarian cancer staging. The objective of this study was to compare the long-term adjustment and QOL of both early and advanced stage ovarian cancer survivors (OCS). Methods: Early and advanced OCS were identified from patient logs. All patients were >3 years from diagnosis and had no evidence of recurrent cancer. Patients were interviewed by phone or in clinic, and the following surveys were administered: EORTC QLQ-C30 (EORTC) and QLQ-OV28 (OV-28), MHI-17, CALGB sexual functioning, FACT Fatigue, Beck's Hopelessness, Fear of Recurrence (FOR), PCL-C post-traumatic stress disorder (PTSD), Unmet Needs, FACT-Spirituality (FACT-Sp), complementary therapy use, and MOS Social Support (MOS). Overall QOL and long-term physical, mental, and sexual effects were compared between the early and advanced stage groups. Results: 58 early stage and 42 advanced pts were interviewed. Except for social functioning (EORTC-social functioning, p< .05;), there were no differences in physical symptoms, functioning and psychological state between the two groups. Anxiety when getting CA125 tested was reported by 59% of early stage and 64% of advanced stage survivors. The percent of survivors scoring at the norm or greater on the MHI Index was 71% for early stage survivors and 64% for advanced stage survivors. The following variables did not differ significantly between the two groups: overall quality of life (EORTC), fatigue (FACT), hopelessness (BECK), spirituality (FACT-Sp), social support (MOS), unmet needs and use of complementary therapy. Psychological assessment revealed that 26% of both the early and advanced OCS had scores indicative of PTSD (PCL-C). Decreased sexual interest attributed to cancer was reported by 54% of early stage and 31% of advanced stage survivors, while 40.5% early stage and 46% advanced stage survivors reported decreased sexual activity attributed to cancer. Conclusions: Long-term QOL and adjustment appear to be independent of initial stage. PTSD and sexual disinterest are important issues for OCS of both early and advanced stage patients in remission.


Abstract Disclosures

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy and are designated with a caret symbol (^) here and in the print version.


  Associated Presentation(s):

    

1. Comparison of the quality of life of early and advanced stage ovarian cancer survivors.

Meeting: 2008 ASCO Annual Meeting
Presenter: Kristina Mirabeau-Beale
Session: Gynecologic Cancer (Poster Discussion)


  Other Abstracts in this Sub-Category:

    

1. Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinum-sensitive ovarian cancer in first relapse.

Meeting: 2008 ASCO Annual Meeting   Abstract No: 5500   First Author: D. K. Armstrong
Category: Gynecologic Cancer - Ovarian Cancer

    

2. Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer.

Meeting: 2008 ASCO Annual Meeting   Abstract No: 5501   First Author: U. A. Matulonis
Category: Gynecologic Cancer - Ovarian Cancer

    

3. A phase III trial of cisplatin plus topotecan followed by paclitaxel plus carboplatin versus standard carboplatin plus paclitaxel as first-line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer (EOC) (OV.16). A Gynecologic Cancer Intergroup Study of the NCIC CTG, EORTC GCG, and GEICO.

Meeting: 2008 ASCO Annual Meeting   Abstract No: LBA5505   First Author: P. J. Hoskins
Category: Gynecologic Cancer - Ovarian Cancer

    

More...


  Abstracts by K. Mirabeau-Beale :

    

1. Comparison of the quality of life of early and advanced stage ovarian cancer survivors.

Meeting: 2008 ASCO Annual Meeting   Abstract No: 5528   First Author: K. Mirabeau-Beale
Category: Gynecologic Cancer - Ovarian Cancer

    

More...


  Presentations by K. Mirabeau-Beale :

    

1. Comparison of the quality of life of early and advanced stage ovarian cancer survivors.

Meeting: 2008 ASCO Annual Meeting
Presenter: Kristina Mirabeau-Beale
Session: Gynecologic Cancer (Poster Discussion)

    

More...


  Educational Book Manuscripts by K. Mirabeau-Beale :

    

No items found.




 
2318 Mill Road, Suite 800, Alexandria, VA 22314   |   phone: (571) 483-1300
© 2005-2009 American Society of Clinical Oncology (ASCO).  All rights reserved worldwide.